3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-galactopyranosyl nitrate | 196398-25-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-galactopyranosyl nitrate
• 英文别名: 3,4,6-tri-O-acetyl-2-azido-2-deoxy-D-galactopyranosyl nitrate；[(2R,3R,4R,5R)-3,4-diacetyloxy-5-azido-6-nitrooxyoxan-2-yl]methyl acetate
• CAS: 196398-25-1
• 化学式: C₁₂H₁₆N₄O₁₀
• 分子量: 376.28
• InChiKey: ZJRHNHIEORAKEY-OZRWLHRGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  158
• 氢给体数：
  0
• 氢受体数：
  12

反应信息

• 作为反应物：
  描述：

  3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-galactopyranosyl nitrate 在 吡啶 、 三氟甲磺酸三甲基硅酯 、 硫酸 、 对甲苯磺酸 、 溶剂黄146 作用下， 以 甲醇 、 硝基甲烷 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Chemoselectively template-assembled glycopeptide presenting clustered cancer related T-antigen

  摘要：

  The first synthesis of the tumor-associated alpha-aminooxy T-antigen 1, a relevant recognition motif for the direct construction of multitopic carbohydrate architecture of biological interest is described. The usefulness of this building block is emphasized with the efficient preparation through oxime ligation of a neoglycopeptide cluster, which is readily suitable for evaluating the role of multivalency in antigen presentation to the immune system from an anticancer vaccine perspective. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2003.10.126
• 作为产物：
  描述：

  1,2,3,4,6-penta-O-acetyl-D-galactopyranose 在 sodium azide 、 ammonium cerium(IV) nitrate 、 4 A molecular sieve 、 氢溴酸 、 copper(II) sulfate 、 锌 作用下， 以 二氯甲烷 、 水 、 溶剂黄146 、 乙腈 为溶剂， 反应 3.0h， 生成 3,4,6-tri-O-acetyl-2-azido-2-deoxy-α/β-D-galactopyranosyl nitrate
  参考文献：
  名称：

  Solid-Phase Synthesis of O-Linked Glycopeptide Analogues of Enkephalin

  摘要：

  The synthesis of 18 N-alpha -FMOC-amino acid glycosides for solid-phase glycopeptide assembly is reported. The glycosides were synthesized either from the corresponding O'Donnell Schiff bases or from N-alpha -FMOC-amino protected serine or threonine and the appropriate glycosyl bromide using Hanessian's modification of the Koenigs-Knorr reaction. Reaction rates of D-glycosyl bromides (e.g., acetobromoglucose) with the L- and D-forms of serine and threonine are distinctly different and can be rationalized in terms of the steric interactions within the two types of diastereomeric transition states for the D/L and D/D reactant pairs. The N-alpha -FMOC-protected glycosides [monosaccharides Xyl, Glc, Gal, Man, GlcNAc, and GalNAc; disaccharides Gal-beta (1-4)-Gle (lactose), Glc-beta-(1-4)-Glc (cellobiose), and Gal-alpha (1-6)-Glc (melibiose)] were incorporated into 22 enkephalin glycopeptide analogues. These peptide opiates bearing the pharmacophore H-Tyr-c[DCys-Gly-PheDCys]- were designed to probe the significance of the glycoside moiety and the carbohydrate-peptide linkage region in blood-brain barrier (BBB) transport, opiate receptor binding, and analgesia.

  DOI：

  10.1021/jo005712m

文献信息

• Synthesis of tumor-associated MUC1-glycopeptides and their multivalent presentation by functionalized gold colloids
  作者：Isabella Tavernaro、Sebastian Hartmann、Laura Sommer、Heike Hausmann、Christian Rohner、Martin Ruehl、Anja Hoffmann-Roeder、Sabine Schlecht

  DOI：10.1039/c4ob01339e

  日期：——

  The authors present the synthesis of novel MUC1-glycopeptide antigens and their multivalent presentation by gold colloids. Their biological activity was tested in a dot-blot immunoassay experiment.

  作者们介绍了新型MUC1-糖肽抗原的合成以及它们在金胶体中的多价展示。它们的生物活性在点印免疫分析实验中得到了测试。
• [EN] TARGETED BIFUNCTIONAL DEGRADERS<br/>[FR] AGENTS DE DÉGRADATION BIFONCTIONNELS CIBLÉS
  申请人：UNIV YALE

  公开号：WO2021072269A1

  公开（公告）日：2021-04-15

  The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

  本发明在一个方面提供了可以用来促进或增强降解某些循环蛋白的双功能化合物。在另一个方面，本发明提供了可以用来促进或增强降解某些自身抗体的双功能化合物。在某些实施方式中，治疗或管理疾病和/或疾病需要降解、去除或减少受试者体内循环蛋白或自身抗体的浓度。因此，在某些实施方式中，将本发明的化合物给予受试者可去除或减少循环蛋白或自身抗体的循环浓度，从而治疗、改善或预防疾病和/或疾病。在某些实施方式中，循环蛋白是TNF。
• [EN] ENGINEERED ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS<br/>[FR] ANTICORPS CONÇUS COMME AGENTS DE DÉGRADATION MOLÉCULAIRE PAR L'INTERMÉDIAIRE DE RÉCEPTEURS CELLULAIRES
  申请人：UNIV YALE

  公开号：WO2021072246A1

  公开（公告）日：2021-04-15

  The present disclosure provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In certain embodiments, the circulating protein mediates a disease and/or disorder in a subject, and treatment or management of the disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein in the subject. Thus, in certain embodiments, administration of a compound of the disclosure to the subject removes or reduces the circulation concentration of the circulating protein, thus treating, ameliorating, or preventing the disease and/or disorder.

  本公开提供了一种双功能化合物，可用于促进或增强特定循环蛋白的降解。在某些实施例中，循环蛋白在受试者中介导疾病和/或紊乱，治疗或管理该疾病和/或紊乱需要降解、去除或减少受试者中循环蛋白的浓度。因此，在某些实施例中，将本公开的化合物给予受试者可去除或减少循环蛋白的循环浓度，从而治疗、改善或预防疾病和/或紊乱。
• A Selectively Deprotectable 2,6-Diaminogalactose Scaffold for the Solid-Phase Synthesis of Potential RNA Ligands
  作者：Horst Kunz、Maciej Madalinski、Michaela Stoll、Ursula Dietrich

  DOI：10.1055/s-2008-1066982

  日期：——

  6-diaminogalactose scaffold was developed for combinatorial syntheses of potential RNA ligands in the solid phase. A set of selectively removable, orthogonally stable protecting groups in combination with a linker stable throughout the synthesis, but selectively cleavable in the detachment process, allows for selective deprotection and introduction of a side chain in each position of this scaffold. A few of

  在氨基糖苷类作为 RNA 的有效结合剂的背景下，开发了一种 2,6-二氨基半乳糖支架，用于在固相中组合合成潜在的 RNA 配体。一组选择性可去除、正交稳定的保护基团与在整个合成过程中稳定但在分离过程中可选择性切割的接头组合，允许在该支架的每个位置选择性脱保护和引入侧链。一些合成的化合物在含有 TAR 控制的报告基因的 HeLa 细胞中表现出对 HIV-1 感染的抑制作用。
• Synthesis of Tn/T Antigen MUC1 Glycopeptide BSA Conjugates and Their Evaluation as Vaccines
  作者：Hui Cai、Zhi-Hua Huang、Lei Shi、Peng Zou、Yu-Fen Zhao、Horst Kunz、Yan-Mei Li

  DOI：10.1002/ejoc.201100304

  日期：2011.7

  The tumor-associated mucin MUC1 over-expressed in most epithelial tumor tissues is considered a promising target for immunotherapy. The extracellular part of MUC1 contains a domain of numerous tandem repeats of the amino acid sequence HGVTSAPDTRPAPGSTAPPA, including five potential O-glycosylation sites. In this study, T9 and S15 have been chosen as the positions of glycosylation. The glycopeptides N-terminally

  在大多数上皮肿瘤组织中过度表达的肿瘤相关粘蛋白 MUC1 被认为是免疫治疗的有希望的靶点。MUC1 的细胞外部分包含氨基酸序列 HGVTSAPDTRAPPGSTAPPA 的众多串联重复结构域，包括五个潜在的 O-糖基化位点。在本研究中，选择了 T9 和 S15 作为糖基化的位置。通过微波辅助 Fmoc 固相肽合成法合成了 N 端带有三甘醇间隔物的糖肽。从树脂上分离并脱保护后，将 MUC1 糖肽与牛血清白蛋白 (BSA) 结合。为了评估免疫学特性，用这些 BSA 疫苗免疫 balb/c 小鼠。